Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Clinical Coagulation Research Unit, Lund University, Skåne University Hospital, Malmö, Sweden.
Haemophilia. 2019 Mar;25(2):244-251. doi: 10.1111/hae.13683. Epub 2019 Jan 28.
Differences in treatment and outcome have been reported for persons with haemophilia (PWH) on intermediate-dose (Dutch) and high-dose (Swedish) prophylaxis, but the potential influence of sports participation has not been considered.
To compare sports participation and clinical outcome between adult Dutch and Swedish PWH.
Self-reported sports participation (type and frequency per week), physical functioning (SF-36 : 100-0), joint status (HJHS: 0-144), perceived limitations (HAL : 100-0) and physical activity (IPAQ) were recorded. Sports were classified according to National Haemophilia Foundation classification (5 categories, highest two were classified as high-risk sports). Sports participation and clinical outcome were compared according to country and age (18-22, 23-29, 30-40 years) using non-parametric tests and Spearman correlations (rho).
Seventy-one adult PWH (NL: 43, SWE: 28) completed sports questionnaires (mean age: 26 years). All participants engaged in sports, including 59.2% in high-risk sports (33.9% twice weekly). Dutch PWH showed a significant age-related decline in (high-risk) sports participation (7x/wk in PWH 18-22 years to 2x/wk in PWH 30-40 years, P < 0.05), joint health (HJHS: median 2-15.5, P < 0.01) and physical functioning (SF-36 : median 100 to 77.5, P < 0.01), while Swedish did not. Sports participation was not associated with bleeding (Spearman's rho = -0.119).
All participants reported sports participation, including 59.2% in high-risk sports. Dutch PWH treated with intermediate-dose prophylaxis showed an age-related decline in sports participation, joint status and physical functioning, whereas Swedish PWH on high-dose prophylaxis did not. Sports participation was not associated with bleeding.
已经报道了接受中等剂量(荷兰)和高剂量(瑞典)预防治疗的血友病患者(PWH)在治疗和结局方面存在差异,但尚未考虑运动参与的潜在影响。
比较成年荷兰和瑞典 PWH 的运动参与和临床结局。
记录自我报告的运动参与情况(每周运动类型和频率)、身体机能(SF-36:100-0)、关节状况(HJHS:0-144)、感知限制(HAL:100-0)和身体活动(IPAQ)。根据国家血友病基金会的分类(5 类,最高两类被归类为高风险运动)对运动进行分类。根据国家和年龄(18-22 岁、23-29 岁、30-40 岁)使用非参数检验和 Spearman 相关系数(rho)比较运动参与和临床结局。
71 名成年 PWH(NL:43,SWE:28)完成了运动调查问卷(平均年龄:26 岁)。所有参与者都参加了运动,包括 59.2%的高风险运动(每周 2 次)。荷兰 PWH 的(高风险)运动参与率与年龄呈显著相关下降(18-22 岁 PWH 每周 7 次降至 30-40 岁 PWH 每周 2 次,P<0.05)、关节健康(HJHS:中位数 2-15.5,P<0.01)和身体机能(SF-36:中位数 100 至 77.5,P<0.01),而瑞典则没有。运动参与与出血无关(Spearman's rho=-0.119)。
所有参与者都报告了运动参与,其中 59.2%的人参加了高风险运动。接受中等剂量预防治疗的荷兰 PWH 随着年龄的增长,运动参与、关节状况和身体机能呈下降趋势,而接受高剂量预防治疗的瑞典 PWH 则没有。运动参与与出血无关。